Search Results - fusion

8 Results Sort By:
Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers
This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...
Published: 7/25/2024   |   Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig
Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Oncology, Application > Therapeutics
Mononegavirales Vectors Expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...
Published: 7/25/2024   |   Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir
Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells
Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is...
Published: 7/25/2024   |   Inventor(s): Wei Bu, Nathan Board, Kennichl Dowdell, Jeffrey Cohen
Keywords(s): ANTIBODY, B, BLOCKS, Cells, DAXXXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DCXXXX, DDXXXX, DXXXXX, EPSTEIN-BARR, Fusion, Infection, Neutralizes, That, virus
Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease
Mononegavirales Vectors expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...
Published: 7/25/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir
Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus
Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 7/25/2024   |   Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath
Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases
Adeno-Associated Virus Gene Therapy for Diabetes and Obesity
This invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis...
Published: 7/25/2024   |   Inventor(s): Giovanni Di Pasquale, Edward Mannucci, John (Jay) Chiorini
Keywords(s): DIABETES, EPITHELIA, Expression, Fusion, GBXXXX, Gland, IBXXXX, Listed LPM Contreras as of 4/15/2015, NGF/exendin-4, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, Salivary, treatment
Category(s): Application > Therapeutics
Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7
Researchers at NIDDK have developed polyclonal antibodies against the Regulator of G Protein Signalling (RGS) protein, RGS7. RGS7 binds tightly to Gbeta5, a unique and highly specialized G protein that exhibits much less homology than other Gbeta isoforms (~50%). RGS7 is preferentially expressed in brain and neuroendocrine tissue. Like Gbeta5, RGS7...
Published: 7/25/2024   |   Inventor(s): Jianhua Zhang, William Simonds
Keywords(s): antibodies, BOVINE, box, Fusion, GST, Includes, Protein, Region, RGS, RGS7, RXXXXX, That
Category(s): Collaboration Sought > Licensing, Application > Research Materials
Myosin-Based Protein-Protein Interaction Assay
Investigators at the National Institute on Deafness and Other Communication Disorders (NIDCD) have developed an assay for the detection of protein-protein interactions in living cells. This assay uses readily-available reagents and straightforward techniques that avoid the difficulty of purifying proteins or generating antibodies required for other...
Published: 7/25/2024   |   Inventor(s): Thomas Friedman, Inna Belyantseva, Erich Boger
Keywords(s): [DC-023], [DC-024], [DC-025], [DC-026], [DC-027], [DC-028], [DC-029], 10, AC4XXX, AC5XXX, ACXXXX, assay, AXXXXX, cDNA, cDNAS, chimeric, Cloning, DsRed-tagged, ELEVEN, Flourescent, fluorescent, Fluorescent probe, Fourteen, Fusion, GFP, GFP-Myo, GFP-Myo10, GFP-MyolO, GFP-myosin, GFp-whirlin, GREEN, HEAVY, HMM, INTERACTION, KINESIN, Meromyosin, Mouse, MYOSIN, ONE, Patent Category - Biotechnology, Plasmic, PLASMID, Protein, PROTEIN-PROTEIN, PROTEIN-PROTEIN interactions, SIX, Sixteen, TAGGED, Twenty, Twenty-two, whirlin, X, XVa
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available
© 2024. All Rights Reserved. Powered by Inteum